Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefepime + ceftriaxone + cefaclor + cephalexin + cefixime + cefdinir-Massachusetts General Hospital-cephalosporin allergy
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Intradermal, Percutaneous
01
Overview
This refers to a specific set of cephalosporin antibiotics—cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, and cefdinir—utilized as diagnostic interventions in a Phase 2 clinical trial conducted by Massachusetts General Hospital. The study, titled 'Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing,' aims to refine diagnostic protocols for patients with suspected cephalosporin allergies. These specific antibiotics are used in double-blind, placebo-controlled drug challenges to assess cross-reactivity based on side-chain chemical similarity. Participants receive escalating doses of a cephalosporin that shares a similar side chain with their 'culprit' antibiotic (the one that caused the initial reaction) to determine the safety and feasibility of using related beta-lactams. As a class, these drugs are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), which are essential for the cross-linking of peptidoglycan.
- Other names
- Similar cephalosporin challengecefepime + ceftriaxone + cefaclor + cephalexin + cefixime + cefdinir
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on cefepime + ceftriaxone + cefaclor + cephalexin + cefixime + cefdinir-Massachusetts General Hospital-cephalosporin allergy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefepime + ceftriaxone + cefaclor + cephalexin + cefixime + cefdinir-Massachusetts General Hospital-cephalosporin allergy.